Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium.
about
Signal transduction in the chronic leukemias: implications for targeted therapiesBiology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinibPractical management of patients with myelofibrosis receiving ruxolitinib.Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing.Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignanciesTargeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasmsMyelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.Myelofibrosis: an update on current pharmacotherapy and future directions.A myeloid tumor suppressor role for NOL3Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories.Comprehensive whole-genome sequencing of an early-stage primary myelofibrosis patient defines low mutational burden and non-recurrent candidate genes.
P2860
Q27026031-2DF2AF73-7C1B-4BE5-9168-68A1DEBD231FQ33402522-52671DEC-82D4-4401-9EBA-EAE819AC6081Q33410649-49A91057-5FDF-4507-8596-AC5B8726D478Q33411763-95BD9A74-A846-4E9E-9670-01F4A2C2D1FFQ35132241-F76D8914-C048-452B-8E43-4AA2F84D70BCQ36359558-8C467F6D-956B-4F8F-93A7-F31945454895Q37168138-07584FFA-73DF-417B-BAC8-5CC4A9C8E000Q37548944-4332AA2E-B64B-4BD4-8503-55CDB99C0C42Q38091447-4012F9AC-8462-4265-A9F7-E330276150B9Q38715127-EB867005-C370-4A33-8B14-B200B00C7756Q42062133-448D84CF-8725-454C-854E-C9F11F4CC8D4Q42077896-5F4661E6-0540-49D9-BA07-61D8E0CDDAE9
P2860
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Unraveling the genetic underpi ...... ernational Post-ASH Symposium.
@en
type
label
Unraveling the genetic underpi ...... ernational Post-ASH Symposium.
@en
prefLabel
Unraveling the genetic underpi ...... ernational Post-ASH Symposium.
@en
P2093
P2860
P50
P356
P1476
Unraveling the genetic underpi ...... ernational Post-ASH Symposium.
@en
P2093
Alessandro M Vannucchi
Animesh Pardanani
Giovanni Barosi
Guido Finazzi
Heinz Gisslinger
Jason Gotlib
John D Crispino
Juergen Thiele
Kapil Bhalla
Mario Cazzola
P2860
P304
P356
10.1002/AJH.23169
P577
2012-03-28T00:00:00Z